Sign in
  Edit search
An adjuvant autologous therapeutic vaccine %2525252528HSPPC-…
An adjuvant autologous therapeutic vaccine %2525252528HSPPC-96%252525253B vitespen%2525252529 versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma%252525253A a multicentre%252525252C open-label%252525252C randomised phase III trial.
An adjuvant autologous therapeutic vaccine %2525252528HSPPC-96%252525253B vitespen%2525252529 versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma%252525253A a multicentre%252525252C open-label%252525252C randomised phase III trial.
Article, Chapter
Authors: C. Wood
Publication: Lancet, The, Volume:372, Issue:9633
Published: Elsevier, 2008
ISSN: 0140-6736
  Full text availability for this item
View Full Text Source:Lancet, The,Lancet, The,Elsevier ScienceDirect Journals Opens in new Window
Journal:  Lancet, The Source:Elsevier ScienceDirect Journals Opens in new Window
Collection:  Elsevier ScienceDirect Journals Opens in new Window
Coverage:
  • 1823-10-05~present; volume:1~present;issue:1~present
Browse related articles
  Print copies at your library
Check availability in RUQuest
  Request a copy of this item
Cite this item